// App-Quantinova.ai

: MUC2MUC5B and TOLLIP variants: no association with disease progression and survival in an IPF cohort

Researchers

Presenter

  • Carmel Stock

Principal Investigators

  • Philip Molyneaux

  • Peter Saunders

  • Maria Kokosi

  • Peter George

  • Vasilis Kouranos

  • Felix Chua

  • Athol Wells

  • Toby Maher

  • Elisabetta Renzoni

Medical Centers

  • Interstitial Lung Disease Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

  • Nintedanib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved